WO2007109615A3 - β -LACTAMYL VASOPRESSIN V2 ANTAGONISTS - Google Patents

β -LACTAMYL VASOPRESSIN V2 ANTAGONISTS Download PDF

Info

Publication number
WO2007109615A3
WO2007109615A3 PCT/US2007/064309 US2007064309W WO2007109615A3 WO 2007109615 A3 WO2007109615 A3 WO 2007109615A3 US 2007064309 W US2007064309 W US 2007064309W WO 2007109615 A3 WO2007109615 A3 WO 2007109615A3
Authority
WO
WIPO (PCT)
Prior art keywords
acids
azetidin
lactamyl
antagonists
vasopressin
Prior art date
Application number
PCT/US2007/064309
Other languages
French (fr)
Other versions
WO2007109615A2 (en
Inventor
Gary A Koppel
Ned D Heindel
Original Assignee
Azevan Pharmaceuticals Inc
Gary A Koppel
Ned D Heindel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2006/010143 external-priority patent/WO2006102283A2/en
Application filed by Azevan Pharmaceuticals Inc, Gary A Koppel, Ned D Heindel filed Critical Azevan Pharmaceuticals Inc
Publication of WO2007109615A2 publication Critical patent/WO2007109615A2/en
Publication of WO2007109615A3 publication Critical patent/WO2007109615A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

β-lactamyl alkanoic acids and pharmaceutical compositions thereof are described. Methods for treating various diseases and disease states using one or more β-lactamyl alkanoic acids are also described. Substituted 2-(azetidin-2-on-l-yl)alkanedioic acids, substituted 2-(azetidin-2-on- l-yl)hydroxyalkylalkanoic acids, and 2-(azetidin-2-on-l-yl)alkylalkanoic acids, and analogs and derivatives thereof are described. Methods for using 2-(azetidin-2-on-l-yl)alkanedioic acids and derivatives thereof in the treatment of disease states responsive to antagonism of the vasopressin V2 receptor are also described.
PCT/US2007/064309 2006-03-21 2007-03-19 β -LACTAMYL VASOPRESSIN V2 ANTAGONISTS WO2007109615A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/US2006/010143 WO2006102283A2 (en) 2005-03-22 2006-03-21 Beta-lactamylalkanoic acids for treating premenstrual disorders
USPCT/US2006/010143 2006-03-21
US79357206P 2006-04-20 2006-04-20
US60/793,572 2006-04-20

Publications (2)

Publication Number Publication Date
WO2007109615A2 WO2007109615A2 (en) 2007-09-27
WO2007109615A3 true WO2007109615A3 (en) 2007-11-29

Family

ID=38523225

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/064309 WO2007109615A2 (en) 2006-03-21 2007-03-19 β -LACTAMYL VASOPRESSIN V2 ANTAGONISTS

Country Status (1)

Country Link
WO (1) WO2007109615A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008534504A (en) 2005-03-22 2008-08-28 アゼヴァン ファーマスーティカルズ，インコーポレイテッド Β-Lactamyl alkanoic acid for treating premenstrual disorders
EP2195328A4 (en) 2007-08-15 2011-06-15 Cytokinetics Inc Certain chemical entities, compositions, and methods
US9376424B2 (en) 2010-07-01 2016-06-28 Azevan Pharmaceuticals, Inc. Methods for treating post traumatic stress disorder
US9802925B2 (en) 2014-03-28 2017-10-31 Azevan Pharmaceuticals, Inc. Compositions and methods for treating neurodegenerative diseases
AU2018333051B2 (en) 2017-09-15 2024-03-21 Azevan Pharmaceuticals, Inc. Compositions and methods for treating brain injury

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040266750A1 (en) * 2001-10-12 2004-12-30 Bruns Jr Robert F Beta-lactamyl vasopressin v1aantagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040266750A1 (en) * 2001-10-12 2004-12-30 Bruns Jr Robert F Beta-lactamyl vasopressin v1aantagonists

Also Published As

Publication number Publication date
WO2007109615A2 (en) 2007-09-27

Similar Documents

Publication Publication Date Title
WO2006102308A3 (en) Beta-lactamyl vasopressin v1b antagonists
WO2007011878A3 (en) Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists
WO2007044804A3 (en) Piperidine derivatives and methods of use
WO2010077883A3 (en) Antagonists of lysophosphatidic acid receptors
WO2007022257A3 (en) Monocyclic and bicyclic compounds and methods of use
WO2008050101A3 (en) Benzoyl amino heterocyclyl compounds useful in the treatment of a disease mediated through glk
MX2009004467A (en) Benzoyl amino heterocyclyl compounds as glucokinase (glk) activators.
MX2020012868A (en) Methods and compositions for sleep disorders and other disorders.
WO2011041694A3 (en) Compounds as lysophosphatidic acid receptor antagonists
WO2007022380A3 (en) Bis-aryl amide compounds and methods of use
EA201100062A1 (en) CONNECTIONS AND METHODS OF MODELING RECEPTORS ASSOCIATED WITH PROTEIN G
EA200701324A1 (en) PYRIDINE COMPOUNDS FOR THE TREATMENT OF DISEASES MEDIATED BY PROSTAGLANDINE
CL2007000161A1 (en) COMPOUNDS DERIVED FROM SUBSTITUTED 2,4-DIOXOIMIDAZOLIDINE, INHIBITORS OF KINE PROTEINS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS CANCER.
WO2010068775A3 (en) Alkyne antagonists of lysophosphatidic acid receptors
WO2008012470A3 (en) Substituted imidazolone derivatives, preparation and uses
MY145349A (en) Benzofuro- and benzothienopyrimidine modulators of the histamine h4 receptor
MY147677A (en) Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
CL2007003690A1 (en) COMPOUNDS DERIVED FROM 1-AZONIA-BICICLO [2.2.2] OCTANO; PREPARATION PROCESS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASES.
CL2008002689A1 (en) Compounds derived from heterocycle 1,4 substituted piperidine; intermediate compounds; pharmaceutical composition; Preparation process; and its use in the treatment of Alzheimer's and schizophrenia.
IL188942A0 (en) Benzimidazole derivatives and pharmaceutical compositions containing the same
IL187966A0 (en) New azetidine derivatives as neurokinin receptor antagonists for the treatment of gastrointestinal diseases
AR066701A1 (en) 3- (IMIDAZOLIL) - PIRAZOLO {3,4-B] PIRIDINES, PHARMACEUTICAL COMPOSITION, PROCESS AND USE IN THERAPY
ATE542795T1 (en) BENZYLPIPERAZINE DERIVATIVES AS MOTILIN RECEPTOR ANTAGONISTS
ZA200805761B (en) Pharmaceutical composition for the treatment of nail disease
CY1113759T1 (en) HIGHLY DISTRIBUTED DOPAMINE COMPETITORS 2

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07758821

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07758821

Country of ref document: EP

Kind code of ref document: A2